期刊文献+

牛磺酸对人宫颈癌细胞侵袭转移的抑制作用及机制研究

Inhibitory Effect of Taurine on Invasion and Metastasis of Human Cervical Cancer Cells and Its Mechanism
下载PDF
导出
摘要 目的探讨牛磺酸(Tau)对人宫颈癌细胞侵袭转移的影响及分子机制。方法采用20~160 mmol/L不同浓度Tau处理宫颈癌Hela细胞24~72 h,CCK8检测细胞增殖活性,Transwell小室检测细胞侵袭与迁移能力,Western blot检测蛋白表达。结果终浓度为40~160 mmol/L的Tau对人宫颈癌细胞增殖和侵袭转移有不同程度的抑制作用(P<0.05),且呈时效和量效关系;同时Tau能增加上皮-间质转化(EMT)代表上皮特征的E-cadherin表达,下调代表间质特征的N-cadherin,Vimentin蛋白及基质金属蛋白酶(MMPs)表达;抑制AKT/GSK-3β通路及降低β-catenin蛋白含量。结论Tau具有抑制人宫颈癌细胞侵袭转移与EMT的作用,其机制可能与AKT/GSK-3β/β-catenin信号通路有关。 Objective To investigate the effect and mechanism of taurine(Tau)on invasion and metastasis of human cervical cancer cells.Methods Cervical cancer Hela cells were treated with Tau at different concentrations for 24~48 h,the proliferative activity of the cells was detected by CCK8;the ability of cell migration and invasion were detected by Transwell assay;Western blot was used to detect protein expression in the cells.Results The results showed that Tau(final concentration 40~160 mmol/L)can inhibit the proliferation,invasion and migration of cervical cancer cells to varying degrees(P<0.05),And showed a certain dose-effect relationship;Meanwhile,Tau increased the expression of E-cadherin,a marker of epithelial-mesenchymal transformation(EMT),and down-regulated the expression of N-cadherin,Vimentin and matrix metalloproteinases(MMPs),inhibited the AKT/GSK-3βpathway and reduced theβ-catenin protein.Conclusion Tau can inhibit EMT,invasion and metastasis of cervical cancer cells,and the mechanism might be related to AKT/GSK-3β/β-catenin signaling pathway.
作者 梁笑倾 万慧芳 刘卓琦 万福生 LIANG Xiaoqing;WAN Huifang;LIU Zhuoqi(The Fourth Affiliated Hospital of Nanchang University,Nanchang,330006)
出处 《实用癌症杂志》 2022年第9期1399-1403,共5页 The Practical Journal of Cancer
基金 江西省卫健委科技计划项目(编号:20181105)。
关键词 牛磺酸 宫颈癌 侵袭转移 上皮-间质转化 信号通路 Taurine Cervical cancer Invasion and metastasis Epithelial-mesenchymal transformation Signaling pathways
  • 相关文献

参考文献5

二级参考文献113

  • 1刘俊丽,陈元,蔡煜,张敏.选择性EGFR酪氨酸激酶抑制剂吉非替尼对宫颈癌离体细胞的放射增敏作用[J].肿瘤防治研究,2007,34(7):480-482. 被引量:8
  • 2Gustafsson L, PontenJ, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:755-63.
  • 3Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
  • 4Monk BJ, Tewari KS, Koh WJ. Mulumodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Onco12007;25:2952-65.
  • 5Tewari KS. Expert panel: patients with metastatic/ recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Clin Ovarian Cancer 2011;4:90-3.
  • 6Monk BJ, Sill MW, McMeekin DS, et al. Phase HI trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
  • 7Tewari KS. A critical need for reappraisal of therapeutic options for women with metastatic and recurrent cervical carcinoma: commentary on Gynecologic Oncology Group protocol 204. Am J Hematol Oncol 2010;9:31-4.
  • 8Tewari KS, Monk BJ. The rationale for the use of non- platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010;8:108-15.
  • 9Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 2005;7:419-34.
  • 10Bonomi P, BlessingJA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079-85.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部